81% of equine worming strategies are not effective in fight against resistance, because owners are not conducting an adequate level of faecal egg counts (FEC), according to a survey carried out by Countrywide, the supplier of equestrian products.
The company surveyed nearly 1,000 horse owners in collaboration with Westgate Laboratories, Norbrook and BW Equine Vets and found that 47% have never conducted an FEC test.
When asked about their current approach to worming, 59% of respondents said they worm at set times of the year with only 31% conducting regular FEC tests.
Mark Hawkins, SQP at Countrywide, said: "With worms becoming resistant to some worming drugs, simply dosing all horses with routine wormers is not adequate. A targeted approach, which considers each horse as an individual, is needed."
Gillian Booth owner at Westgate Laboratories said: "The results show that the majority of horse owners are not updating their worming practice to match the increase in resistance and improvement in testing technology. Previous worming practices have led to the resistance problems we now have so it is vital that there is change."
The survey found that veterinary surgeons and in store advisors are vital to promote change - 65% of respondents actively seek advice from their vet and Suitably Qualified Person (SQP) for worming and general health care.
Mark added: “A huge 99% of people worm their horse at least once a year; despite this 38% of horse owners do not know an accurate weight of their horse. Considering inaccurate dosing plays a large role with the increase in resistance this figure is very concerning. If you do need to treat, accurate dosing is essential.”
The survey found that 86% of respondents had wormed for tapeworm, making it the most wormed for parasite. Despite this, only 6% of horse owners had conducted a saliva test for tapeworm, and only 8% had conducted the more established ELISA blood test through their vet to prove the need for this worming dose.
For a full breakdown of the survey results, visit: www.countrywidefarmers.co.uk/wormingsurvey.
Leading equine veterinary surgeon Ian Wright has been setting a legal precedent this week, as the Court of Appeal ruled that his ex-wife could not expect him to continue to fund her lifestyle and that she should earn her own living.
Ian, an RCVS Specialist in Equine Surgery and a partner at the Newmarket Equine Hospital, divorced his wife Tracey in 2008 after 11 years of marriage. As part of the settlement, Mrs Wright was given a £450,000 house and Mr Wright was ordered to pay £75,000 per annum, which included £33,200 spousal maintenance.
Last year, Mr Wright, 59, went to the High Court to ask for a reduction in maintenance, arguing that it was unfair to expect him to continue to fund his ex-wife indefinitely, even after he retired at 65, when she made no effort to find a job and support herself.
The case was heard by Judge Lynn Roberts, who agreed there was no reason why Mrs Wright had not worked in the six years since her divorce and said she had been: "evasive on the subject of her own earning capacity".
Mrs Wright challenged the decision in the Court of Appeal this week, where Lord Justice Pitchford rejected her fight to have her future maintenance reinstated, saying: "There is a general expectation that, once children are in year two, mothers can begin part time work and make a financial contribution" and: "The time had come to recognize that, at the time of his retirement, the husband should not be paying spousal maintenance".
Speaking to The Times, Mei-Ling McNab, a partner at Brachers law, said: "This landmark decision provides some much needed clarity and will be a game-changer for future big-ticket divorce cases. The ruling confirms that mothers with children aged over seven should have financial responsibility to support themselves."
The British Equine Veterinary Association (BEVA) is urging veterinary surgeons to be on the lookout for outbreaks of Atypical Myopathy (AM) this spring.
Atypical Myopathy is a serious muscle disease found in the UK and Northern Europe. It is linked to horses eating the seeds from trees in the Acer family, including sycamore and box elder. There were more than five times as many cases of AM last autumn than in the previous year and experts have warned that the disease tends to occur more frequently in the spring following an autumn surge, possibly because of the growth of seedlings. The prognosis is poor, with survival rates of less than 25%. Early diagnosis is essential to give the best chance of survival.
Horses that develop AM are usually kept on sparse pastures, near trees from Acer pleudoplatanus (sycamore) or Acer negundo (box elder, pictured right) that shed seeds containing the toxin hypoglycin A. They are often not fed any supplementary hay or feed and may be driven to browse on an accumulation of dead leaves, dead wood and trees in or around the pasture but sometimes well-fed animals are affected. While the tree seeds may not be directly palatable, horses on poor quality grazing may ingest considerable numbers of them.
The clinical signs of AM may include muscle weakness or stiffness, colic-like symptoms, laboured breathing, dark red-brown urine, recumbency or even sudden death. Often the disease will present as an outbreak. Confirmation of diagnosis is by a blood or urine test. The toxin directly targets aerobic energy metabolism so therapy should be targeted at promoting glucose metabolism and provided fluid dieresis.
Preventative advice for horse owners includes:
Professor Celia Marr, Partner at Rossdales, Newmarket, European Specialist in Equine Internal Medicine and Editor of Equine Veterinary Journal said: "New, collaborative research, instigated last year between the University of Liege, the Irish Equine Centre and the Animal Health Trust should shed more light on the characteristics of the disease in this country. Once we know more about the specific causes we should be able to make more positive progress with prevention strategies."
BEVA has provided free online access to two articles from the journal of Equine Veterinary Education on the disease for all vets to help them address the threat.
Volume 25, Issue 5, pages 264-270, May 2013
Management of cases suffering from atypical myopathy: Interpretations of descriptive, epidemiological and pathophysiological findings. Part 1: First aid, cardiovascular, nutritional and digestive care (pages 264-270) G. van Galen and D -M Votion.
Volume 25, Issue 6, pages 308-314, June 2013
Management of cases suffering from atypical myopathy: Interpretations of descriptive, epidemiological and pathophysiological findings. Part 2: Muscular, urinary, respiratory and hepatic care, and inflammatory/infectious status (pages 308-314) G van Galen and D - M Votion.
The Animal Health Trust is appealing to veterinary surgeons and nurses to encourage clients who keep their horses on premises that have been affected by Equine Grass Sickness to sign up to the second year of its nationwide EGS vaccine trial.
Equine Grass Sickness (EGS) occurs predominantly in Europe, with Britain experiencing the highest incidence worldwide. In 2014, 59 cases of EGS were reported through the EGS Surveillance Scheme, but it is likely that this represents only a fraction of cases occurring annually throughout Britain.
Almost all cases of EGS occur in horses with access to grazing. The AHT says there is growing scientific evidence to suggest that the disease may be caused by the bacterium Clostridium botulinum type C, commonly found within soil and capable of producing neurotoxins to which horses are particularly sensitive. EGS occurs when a combination of risk factors trigger the production of these toxins within the horse's intestinal tract, causing damage to the nervous system and paralysis of the gut.
As similar equine diseases such as tetanus and botulism can be prevented by vaccination, it is theoretically possible that a vaccine could prevent EGS. To this end the AHT, in collaboration with the Universities of Edinburgh, Liverpool and Surrey launched the EGS field vaccine trial in 2014 in order to establish whether a vaccine could indeed be effective in reducing the risk of the disease. The trial is funded by a number of sources including Neogen Corporation; Animal Welfare Foundation; Horserace Betting Levy Board; Racing Foundation; Moredun Foundation Equine Grass Sickness Fund; Hong Kong Jockey Club; The British Horse Society and the EB Moller Charitable Trust.
Now entering its second year, the EGS vaccine trial involves enrolled horses and ponies receiving either a course of the C. botulinum type C toxoid vaccine or an inactive placebo, as well as an annual booster. The incidence of EGS is monitored throughout the trial to determine the efficacy of the vaccine, and enrolled horses and ponies are closely monitored through regular follow-ups for the duration of the trial.
With 60% of EGS cases occurring during April - June, the highest risk season for EGS is fast approaching. The AHT is appealing to owners who keep their horses on premises that have had at least one case of EGS in the past three years to enrol their horse in the vaccine trial and provide an invaluable contribution to this pioneering research prior to these high risk months. Veterinary practices with clients who fit this description are asked to help the recruitment process by encouraging suitable cases to sign up to the trial.
Dr Jo Ireland, the AHT's Equine Grass Sickness Research Co-ordinator, said: "We have been delighted with the overwhelmingly positive response to the EGS vaccine trial and many owners have welcomed the chance to be a part of such important research. We don't want any eligible horse owners to miss out on the opportunity to contribute towards a potential breakthrough in the prevention of EGS, so we are encouraging more owners to enrol their horses on the trial this year."
To find out more about the vaccine trial or how clients can enrol horses and ponies, visit the AHT's dedicated EGS website www.equinegrasssickness.co.uk or email equinegrasssickness@aht.org.uk.
MSD Animal Health's equine division has launched a new series of materials to support its Keeping Britain's Horses Healthy Campaign.
For veterinary practices, there's a Vet Reception Pack designed to help receptionists educate owners why they should vaccinate and the benefits of preventive healthcare.
For yards, there are posters giving guidance and advice on prevention of Infectious Respiratory Disease and the steps which should be taken to control a potential outbreak. They can be tailor made for an individual yard.
Peter Young, MSD Animal Health Equine Business Manager said: "Our first wave of support materials focused very much on equine vets and owners - helping raise awareness of the importance of preventive healthcare and driving owners towards vets for advice. This phase of materials helps support yard owners and receptionists, aiming to fill some of those communications gaps where advice and guidelines on individual horse's vaccination requirements and yard protocols can play a vital role in preventing the spread of disease and controlling outbreaks."
Keeping Britain's Horses Healthy is a national campaign to educate horse owners on endemic infectious disease, vaccination, herd immunity and the importance of preventative healthcare. It includes a range of educational materials for veterinary surgeries and direct to owners. The campaign is supported by a national PR, advertising and social media programme, together with a dedicated website www.healthyhorses.co.uk. The website, aimed at driving owners back to their veterinary practices, includes a vet finder, exclusively for equine practices, and healthcare information.
For full details of the launch programme, talk to your account manager, call 01908 685685 or visit www.healthyhorses.co.uk.
Ceva Animal Health has announced that Vetergesic (buprenorphine), its long-lasting analgesic, is now back in stock and on special offer with the rest of the company's analgesic product range.
The company says it has appointed a new, dedicated Vetergesic manufacturing site and increased stock-holding facilities in order to guarantee a continuous long-term supply of the product, which is available in a 10ml vial for use in dogs, cats and horses and a 1ml single dose preparation for cats and dogs.
At the same time, Ceva has launched a spring offer on its entire analgesic product range, which runs till the end of April. For every two packs of Vetergesic, Carprodyl F or Dolagis purchased, veterinary practices will receive one pack free and for every four packs of Meloxidyl purchased, practices will receive one pack free. In addition, practices will be able to take advantage of ongoing rebates through the new CevaSave Rebate Programme.
For further information, contact your local Ceva territory manager, email analgesics-group@ceva.com or call 01494 781510.
The Waltham Equine Studies Group has announced the results of two pieces of research designed to improve understanding of the best nutritional support for older horses, whether they are healthy or diagnosed with Pituitary Pars Intermedia Dysfunction (PPID or Cushing's).
The first study: A comparison of nutrient digestibility between adult and aged horses, conducted by the Department of Large Animal clinical Sciences and Animal Science, Michigan State University and The Waltham Equine Studies Group, confirmed (in contrast to earlier work) that there was no difference in digestibility between healthy adult and aged horses when fed a variety of common equine diets.1
In the second study: Characterisation of the faecal bacterial community in adult and elderly horses fed a high fibre high oil or high starch diet, the Institute of Biological Environmental and Rural Sciences, Aberystwyth University, The Waltham Equine Studies Group and Michigan State University used the same horses as the previous study but this time looked at their gut microflora. The results showed that although no significant differences in individual species of bacteria were found, ageing was, however, associated with a reduction in bacterial diversity. This, say the authors, may in part explain why older animals can be at increased risk of intestinal disturbances.2
An abstract that summarised part of the Waltham Equine Studies Group's work on the effect of additional supplementation on aged horses with and without PPID was presented at the 2nd Dorothy Havermeyer Geriatric Workshop in the USA last November.3 This work, carried out in conjunction with Dr Amanda Adams at the University of Kentucky showed that age is key in influencing inflammation and metabolism rather than whether the horse is PPID positive or not.
Professor Pat Harris, head of the Waltham Equine Studies Group, said: "For the parameters we monitored, the research showed that it is being old that is the issue, rather than having PPID."
Clare Barfoot RNutr and the research and development manager at Spillers said: “This should give us a better understanding of the effects of diet and age on metabolism in order to determine optimal nutrition for the senior horse. Preliminary work suggests that this new research may change the way we think of feeding the older horse. Waltham’s work continues to ensure that Spillers feeds remain at the forefront of equine nutrition, for the better health of horses everywhere.”
References
John Kenward MRCVS, a director of Maidstone practice Pet Emergency Treatment Services, has been given a conditional discharge for allowing an employee to X-ray her own foot after a horse stamped on it.
Maidstone Magistrates heard that the employee, a 25 year-old vet and equine intern, was afraid the foot was broken and she might be unable to do that evening's on-call duty.
As a result, she rang Mr Kenward. As they were both concerned she could be held up in hospital A&E, Mr Kenward suggested she use the in-house X-ray kit. He gave her the settings to use and she carried out the test, which showed no break so she continued to work as normal.
Another director, who acts as Radiation Protection Supervisor, later noticed a human image on the digital processor. This led him to notify other practice board members of his intention to interview staff about the suspected breach of site radiation safety policy. He was immediately told by Mr Kenward not to discipline the vet intern as he had suggested that she use the X-ray.
As a result the Health and Safety Executive was contacted and an investigation confirmed a breach of radiation regulations.
Although the vet intern, from Maidstone, was the only person present during the X-ray exposure, she did not wear a personal dosemeter during the procedure.
However, HSE told the court that Mr Kenward was fully aware that the rules of the practice clearly stated nobody should be placed within the beam of the X-ray machine.
Mr Kenward was ordered to pay £1,296 in costs after admitting a breach of the Health and Safety at Work etc Act 1974.
After the hearing, HSE inspector Rob Hassell said: "Any vet practice using ionising radiation for medical exposures must ensure that the X-ray equipment is properly maintained and that the requirements of the Ionising Radiations Regulations are complied with. The view of HSE and the Department of Health is that it is highly unlikely that all these conditions can be met by a veterinary practice.
"It follows therefore that X-rays must not be taken of human beings at practices. We are aware that the X-raying of people may not be unique to this particular practice so I hope others will take note that HSE is prepared to prosecute if such breaches come to light."
Dechra Veterinary Products has launched a new 50 ml bottle of its rapid acting dissociative anaesthetic licensed for cats, dogs and horses, Anesketin.
Anesketin solution for injection, containing Ketamine 100 mg/ml, is indicated for induction of anaesthesia.
Dechra Brand Manager Craig Sankey said: "Anesketin has proved to be a very popular product in our range due to its versatility. It can be used in combination with appropriate sedatives and analgesics in cats, dogs and horses for induction of anaesthesia.
"As it does not require any special temperature storage conditions it makes it a very portable product for vets on the move."
He added: "We are very pleased to be able to add the larger Anesketin product to our wide range of analgesics and sedatives. This demonstrates our commitment to offering high quality products that support vets in small animal and equine practice."
Dechra says the product can also be used as a sole agent for restraint and minor surgical procedures where muscle relaxation is not required in cats.
Anesketin is also available in 10 ml vials. For further information, visit www.dechra.co.uk
Merial has announced the UK launch of updated ProteqFlu, the first and only EI vaccine in Europe to contain a clade 2 strain.
The company says the new vaccine is also the only one that is fully compliant with the latest 2014 OIE recommended EIV strains.
Louise Radford MRCVS from Merial said: "The launch marks the UK's first and only fully updated equine flu vaccine that contains both a Clade 1 and Clade 2 antigen which includes protection against the latest Florida Clade 2 strain, Richmond 07. This is a significant step for horse health, and the equine industry as a whole."
Hervé Poulet, Merial's head of BioDevelopment and BioResearch said: "Merial has developed strong and unique expertise in the development of non-replicative recombinant canarypox virus-vectored vaccines for various species and diseases.
"For the development of ProteqFlu, our non-replicative recombinant canarypox vector expressing the EI virus haemagglutinin (HA) is used because of its ability to induce a strong cellular immunity which is an essential component in protecting against this highly contagious disease."
Louise added: "ProteqFlu has also demonstrated its success and efficacy in real outbreaks, particularly during the last major outbreak, in Australia in 2007. ProteqFlu was the only vaccine chosen for the eradication programme."
Academics from the University of Bristol's School of Veterinary Sciences and the neurology team at Southmead Hospital Bristol have published the results of study examining the use of percutaneous electrical nerve stimulation (PENS) therapy as a treatment for headshaking syndrome in horses.
The authors say that the condition, a neuropathic facial pain syndrome, often leaves affected horses impossible to ride and dangerous to handle, and can result in euthanasia. At present there are no consistently safe and effective methods for the treatment of headshaking in horses, and the condition is estimated to affect between 10,000 and 20,000 horses in the UK.
The study, which is published in the Equine Veterinary Journal (EVJ), aimed to discover whether PENS therapy, developed by Algotec Research and Development Ltd, is safe, effective and sustainable for the management of trigeminal-mediated headshaking in horses.
Seven horses diagnosed with trigeminal-mediated headshaking were recruited to the trial. All procedures were carried out in sedated horses with a needle-prick sized area of skin desensitised with local anaesthetic to help probe insertion. A disposable PENS probe was placed just beneath the skin adjacent to the nerve under ultrasonographic guidance. The nerve was stimulated for 25 minutes following a protocol of alternating frequencies and a perception threshold based on human clinical data. The probe was removed and the procedure repeated on the other side. Three or four treatments were used during the protocol, with treatments being repeated when signs of headshaking recurred.
All horses tolerated the procedure well. Three horses developed a haematoma at the site on one occasion and two had increased clinical signs for up to three days following first treatment. Six horses responded well after the first treatment and returned to ridden work at the same level before headshaking began. Five horses continued to respond to further treatment.
Veronica Roberts, Senior Clinical Fellow in Equine Medicine in the University's School of Veterinary Sciences, who led the study, said: "Headshaking in horses is a major welfare issue and can be a significant cause of distress.
"Although it is clear that further work is required, including increasing the number of cases and refining the treatment procedures, the study shows that PENS therapy should be the first-line treatment for trigeminal-mediated headshakers, which have failed to respond to conservative treatment, such as nose-nets."
Reference
Elanco Animal Health has launched Vulketan, a POM-V sterile topical gel developed to encourage the healing of equine wounds.
Vulketan contains ketanserin - a serotonin-S2 antagonist.2 Elanco says that although serotonin is more widely known as a neurotransmitter in the brain, it is also found in platelets and released during platelet aggregation where it can have negative effects on wound healing.4, 7
Managing equine wounds is an everyday occurrence in equine practice1 and can be difficult and time-consuming, with many potential complications such as infection or the development of proud flesh which could delay healing or lead to reduced functionality. Repeated dressings can be a hassle for owners, and if used inappropriately can lead to their own complications.5
Elanco representative Kirsty Prudon said: "Vulketan gel is easy to use and is designed to be applied to undressed wounds, although it has been demonstrated that wounds may be dressed, if required, without affecting Vulketan's efficacy2,6.
Elanco also points to studies which it says demonstrate that Vulketan has been shown in client owned horses to be highly effective in preventing the formation of hypergranulation tissue and may facilitate the control of secondary infections.2,3,6. In addition, owners expressed satisfaction with Vulketan in over 90% of cases.6
Practising equine vet Linda Belton MRCVS said: "Vulketan is easy to use, well tolerated by horses and produces an excellent end cosmetic result and return to function. With the reduction in the need for dressings and proud flesh control Vulketan has proven to be an advantageous product which owners value."
Vulketan is suitable for use in all horses including pregnant and lactating mares. It is supplied in 75 gram tubes and should be applied twice daily.
For more information, contact your Elanco territory manager call Elanco on 01256 353131.
Boehringer Ingelheim Vetmedica has launched Equisolon 33 mg/g oral powder, the first licensed oral prednisolone for the alleviation of inflammation associated with recurrent airway obstruction (RAO), otherwise known as heaves, in horses.
Clare Turnbull, equine brand and technical manager at Boehringer Ingelheim Vetmedica said: "Oral glucocorticoids are sometimes necessary for treating the inflammation associated with RAO. We feel it is important that when our customers need to use prednisolone for their cases, there is an equine specific product available to them that is easy to dispense and administer."
The company says Equisolon should be used in combination with environmental measures to treat RAO.
For further information on Equisolon, contact your Boehringer Ingelheim Vetmedica equine representative or call +44 (0)1344 746959.
The British Equine Veterinary Association (BEVA) has clarified regulations on equine dental procedures following a survey which showed confusion, even amongst vets, over who is allowed to do what in a horse's mouth.
In the survey of BEVA members, more than half were unaware of the dentistry techniques that equine dental technicians (EDTs) are permitted to perform and the levels of veterinary supervision required.
In response, the association has put together a new information leaflet which explains the regulations surrounding equine dental care and describes where recommended practice differs from the letter of the law.
All diagnostic and treatment procedures in the horse's mouth are Acts of Veterinary Surgery under the Veterinary Surgeons Act 1966. The only exception is the manual removal of small dental overgrowths and sharp enamel points with hand instruments.
However it is acknowledged that there are a limited number of procedures that, despite being considered Acts of Veterinary Surgery, may be delegated safely to suitably qualified EDTs without compromising the horse's welfare and safety. In 2009 the RCVS, with assistance from BEVA, BVDA and BAEDT, listed these processes and categorised all dental procedures into three groups:
Despite there being no legal basis supporting non-vets performing Category 2 procedures, the RCVS has stated that there would be no public interest in prosecuting vets who collaborate with suitably qualified EDTs to perform non-invasive (Categories 1 and 2) procedures.
BEVA recommends that, for their own protection, all vets who deal with horses:
Vicki Nicholls, equine vet at Wright and Morten in Cheshire, chair of BEVA council's Paraprofessional Committee and member of the British Association of Equine Dental Technicians (BAEDT) said: "The lack of awareness is alarming and clearly emphasises the need to make vets and equine dental technicians fully conscious of current regulations regarding equine dentistry. Non-adherence to the regulations is a serious matter and could lead to prosecution of the veterinary surgeon, EDT and/or owner."
The number of vets taking the BEVA/BVDA exam in equine dentistry has increased in recent years with about 15% of those who have passed the exam being vets. BEVA says this is indicative of the growing awareness, amongst owners and vets, of the importance of dental health. It also reflects a desire to develop and demonstrate both practical skills and a theoretical understanding of equine dental care to augment the vet's broader medical knowledge. Expertise in equine dental care has, for many veterinary practices, become a valuable asset.
Copies of the dental regulations information leaflet can be downloaded from the BEVA website at www.beva.org.uk. BEVA also runs regular dentistry CPD courses, details of which can be found on the website.
Image source: Rachel C from Scotland
This year's National Equine Health Survey, conducted by the Blue Cross and supported by Zoetis, has revealed that 20% of owners who claimed to have treated for encysted small redworm (ESRW) used a wormer that was not indicated to treat the parasite.
3,669 horse owners took part in the survey, which was conducted in May 2014. It contained 25 questions on general horse health, care and management and was validated by Professor Josh Slater at the Royal Veterinary College.
Zoetis says the findings suggest that horses are being left at serious risk (untreated, encysted small redworm may develop and emerge en masse from the gut wall, causing diarrhoea and colic with a mortality rate of up to 50%1).
The company is now running an encysted small redworm awareness campaign at www.esrw.co.uk, where owners can test their knowledge before discussing the best treatment options with their vet.
1. Dowdall S.M.J. et al (2002) Veterinary Parasitology 106, 225‑242
BCF has announced the launch of the wireless Cuattro Slate 4 equine DR system.
BCF says the new system is available with an Automatic Exposure Detection (AED) panel, which means the plate automatically recognises the radiation from the generator, with no need for a sync cable.
Gavin Mitchell from BCF said: "This system now makes the connection from any generator to the plate and from plate to tablet now wireless. This is the new revolution for equine DR. Our rugged tablet design makes it easy to show your client your images. All you need to carry with you is the plate, tablet and generator. So much lighter to transport than previous DR systems and now also easier to move around the horse."
Sarah O'Grady from BCF added: "The powerful Cuattro software is so intuitive to use, allowing you to easily customise how your image looks. A simple three step process to take an image and just one button press to back-up images to PACS or the Cloud, makes the Slate so easy to use. If you are considering upgrading to DR or replacing your old DR system, then make sure you try out the new Slate 4."
For more information, visit www.bcftechnology.com or ask your local Account Manager for a free trial.
Zoetis has launched UlcerGold (omeprazole) for the treatment - and prevention of recurrence - of gastric ulcers in horses and foals, presented in a syringe suitable for foals from four weeks of age and horses from 70 to 700kg.
Equine Gastric Ulceration Syndrome (EGUS) is a serious and common condition affecting horses and foals.2,3 Approximately 90% of racehorses, 60% of performance horses, 37% of leisure horses and 50% of foals have been shown to be affected.2,4,5 The condition is associated with injury to the mucosa of the oesophagus, stomach and duodenum, with prolonged exposure to gastric acid thought to be the primary cause.2,3 Risk factors include stress, intense exercise, a high-grain diet, intermittent feeding and illness.2,3 EGUS can have a profound impact on a horse's condition and performance and can ultimately be life threatening, especially in foals.3,5 It is a challenging condition to diagnose as the clinical signs are often vague and not always present.3 Gastroscopy is the only method currently available for a definitive diagnosis and treatment is usually based on acid suppressive therapy to allow ulcer healing.2
UlcerGold is indicated to treat and prevent the recurrence of gastric ulcers in horses, administered once-daily for 28 consecutive days at the full dose of 4mg/kg bodyweight followed by the reduced dose of 1mg/kg bodyweight for a further 28 days.1 It contains omeprazole, a proton pump inhibitor that suppresses gastric acid secretion.1,2 One syringe contains enough UlcerGold for a horse weighing up to 700kg. It can be used for foals as young as four weeks of age that weigh over 70kg and for breeding stallions.
Zoetis says UlcerGold is supported by a comprehensive gastroscope training programme, pricing model, client support and communications plan to ensure that it is a strong asset to veterinary businesses.
Penny McCann, Equine Product Manager, Zoetis UK Ltd, said: "UlcerGold is an exciting addition to our equine POM-V portfolio. We have designed a training, education and business programme to help practices make sure they get the best from our new product, not only in terms of gastric ulceration treatment but also practice health."
Andrew Harrison, a partner at Three Counties Equine Hospital in Gloucestershire, has been appointed as the new President of the British Equine Veterinary Association (BEVA) for 2014/15.
Andrew took over the role from Paul Jepson at the end of BEVA Congress last week. Mark Bowen, Associate Professor of Veterinary Internal Medicine at The University of Nottingham School of Veterinary Medicine and Science, becomes President Elect.Andrew said: "It is a privilege and an honour to take up the presidential reins for the next 12 months. It is unrealistic to expect to "change the world" in such a short time frame so the plan is to target certain areas, such as progressing New Safer Horse Rescue courses, strengthening BEVA's relationship with the BHA and moving forward with the regulation of Musculoskeletal Paraprofessionals. Not least it is a priority this year to make sure we keep aspiring vets realistically informed about future employment in our profession given the proliferation of undergraduate places available at UK and English speaking mainland European vet schools."
For further information visit www.beva.org.uk.
The British Equine Veterinary Association has published the results of a survey it commissioned which found that horse vets in the UK are probably at greater risk of injury than any other civilian profession, including the prison service.
For the study, which was conducted by the Institute of Health and Wellbeing and the School of Veterinary Medicine at the University of Glasgow, 620 equine vets completed a work-related injuries questionnaire. The results of the study indicated that an equine vet could expect to sustain between seven and eight work-related injuries that impeded them from practicing, during a 30-year working life.
If the 620 respondents were representative of the rest of the profession, the injuries they reported would equate to 26,452 per 100,000 equine vets in employment per year. That compares with 10,760 for people working in the prison service, 8,700 for policemen below the rank of sergeant, 6,980 for welders, metal formers and related trades, and 4,760 for construction workers.
Participants were asked to describe their worst-ever injury. Most were described as bruising, fracture and laceration, with the most common site of injury being the leg (29%), followed by the head (23%). The main cause of injury was a kick with a hind limb (49%), followed by strike with a fore limb (11%), followed by crush injury (5%). Nearly a quarter of these reported injuries required hospital admission and notably, 7% resulted in loss of consciousness. The most common reason for the examination during which the injury occurred was foot lameness, followed by dental and female reproductive.
BEVA Past-President Keith Chandler said: “We were shocked to discover the extent of the injuries sustained. Of greatest concern is the number of vets who suffered head injuries and unconsciousness. These injuries appeared to be more common when certain procedures were being performed, such as endoscopy of the upper respiratory tract, when vets are often only partly sighted while using examination equipment, or during wound management and bandage-changes, where vets are often crouched-down for long periods, next to the patient.”
38% of the ‘worst’ injuries occurred when the vet was working with a ‘pleasure’ horse and most frequently (48% of all responses) the horse handler was the owner or the client at the time of the injury. Whilst the number of laypersons or handlers injured at the same time was low, Tim Parkin, vet and lead researcher, pointed out: “This work should act as a wake up call to all involved in the training, employment and engagement of equine vets. The risks associated with handling and working with horses should be the primary consideration for equine vets and horses owners alike, every time a horse is examined or treated. In addition, the experience of the horse handler should be considered when undertaking riskier procedures.”
David Mountford, Chief Executive of BEVA said: “The results are very concerning and justify a careful prospective scientific quantification of the risks. In the short term, knowledge of these risks allows us to better inform all vets who work with horses. In turn vets will be able to inform horse owners, horse-keepers and trainers of the risks, and this may provide justification for having trained assistance on-hand or the more extensive use of sedative drugs in practice, potentially reducing the risk of injury.
"The British Equine Veterinary Association will now look to work with the Health and Safety Executive, Veterinary Schools, large employers of vets in the UK and our members to help develop policies to mitigate the risk of serious injury for vets working with horses.”
Photograph courtesy Towcester Veterinary Centre
Dechra Veterinary Products has launched Osphos, an intramuscular clodronic acid injection for the control of clinical signs associated with the bone resorptive processes of navicular syndrome in horses, the only such licensed product in the UK.
Dechra says it expects Osphos to change the way chronic lameness caused by navicular syndrome is tackled by equine vets.
According to the company, clinical trials of Osphos showed 74.7% of horses experienced improvement by at least one lameness grade at 56 days post treatment.
Dechra brand manager Emma Jennings said: "Osphos intramuscular injection contains the bisphosphonate clodronic acid which inhibits resorption in the navicular bone by binding to hydroxyapatite crystals and by direct cellular effects on osteoclasts.
"We are delighted with the results of the trials, which proved that Osphos is effective at 6 months post-treatment. We're looking forward to being able to support equine vets, vet nurses and practices by providing an intramuscular Clodronic acid injection for horses."
Dechra also says studies showed that mild transient colic was seen following just 1.6 per cent of treatments.
Osphos 60 mg/ml solution for injection for horses is available from September 2014.
The Royal Veterinary College and the Animal Health Trust are trying to recruit 3000 horse and pony owners to take part in 'CARE about laminitis', a web-based research project that aims to reduce the threat caused by laminitis.
The four-year study, which is being funded by World Horse Welfare, is being conducted by PhD student, Danica (Dee) Pollard, based at the AHT. The main aims of the study are to:
Currently the veterinary-reported frequency of laminitis in Britain, estimated between 2009 and 2011, shows that active episodes of veterinary-diagnosed laminitis occurred in nearly 1 in 200 horses/ponies registered with veterinary practices, and accounted for nearly 1 in 200 equine visits. Dee said: "However an overall lack of studies into the frequency of laminitis leaves little to compare these estimates with."
If you'd like to take part in the study, or invite clients to do so, visit: www.careaboutlaminitis.org.uk or email danica.pollard@aht.org.uk.
Merial is inviting all equine veterinary surgeons that are going to BEVA Congress this year to the launch of updated ProteqFlu, its equine flu vaccine which now includes protection against the latest Clade 2 strains, including Richmond 07.
Speakers at the event include specialist Dr Richard Newton (pictured right), Head of Epidemiology and Disease Surveillance at the Animal Health Trust (AHT), and Dr Romain Paillot Head of Immunology at the AHT. Dr Newton will explain why the inclusion of the Clade 2 strain is so important for horse health, and the equine industry as a whole.
Louise Radford MRCVS from Merial said: "We're all incredibly excited as the event will mark the launch of the UKs first and only fully updated equine flu vaccine that contains both a Clade 1 and Clade 2 antigen. The new ProteqFlu® vaccine fully represents the latest 2014 OIE recommended EIV strains."
The launch is being held at the Hotel Du Vin, Birmingham on Thursday 11 September 2014. Presentations will cover 'A virological and immunological perspective on Clade 2 & EIV', 'How technology makes the difference' and independent vaccine trial results.
The evening starts at 6.30pm and includes dinner and evening entertainment.
To book, contact, Jo Gater-Willats, or Merial Customer Support on 0800 6000123.
New research from the Animal Health Trust (AHT), published in the Equine Veterinary Journal, shows that equine obesity is an increasing but under-recognised welfare issue in the UK.
Data collected from 785 horses and ponies (31% of which were classified as obese), over a two-year period between 2009 and 2011, has been used to explore various elements that contribute to the risk of obesity in British horses and ponies.
The research, funded by World Horse Welfare, identified several factors which may increase the risk of being obese. Pony breeds, particularly UK native breeds and heavier horses such as draught and cobs types were all significantly more likely to be obese compared to Thoroughbred horses. Charlotte Robin, Research Assistant at the AHT and lead author of the paper, said: "Native breeds may be genetically better adapted to survive in harsh conditions, having a so-called thrifty genotype, increasing their risk of obesity when maintained in an environment where food is of better quality and more readily available."
Horses that were described by their owners as readily being able to gain weight or being "good doers" were more than three times more likely to be obese, compared to those that normally maintained weight.
The research also highlighted various links to human obesity. Charlotte said: "In humans, obesity is associated with poor health status and chronic health conditions including diabetes, hypertension, respiratory disease and arthritis. Similar associations between obesity and adverse health events have been described in equines."
Similarly in humans, exercise significantly improves insulin sensitivity, and it is thought the same "dose-response" effect is mirrored in horses. For example, the AHT's research highlighted that the risk of obesity is greater in pleasure or non-ridden horses, with pleasure horses being more than twice as likely to be obese and non-ridden horses being nearly three times more likely to be obese. Competition animals will receive increased exercise at a higher intensity and be fitter than non-competition animals, further reducing the risk of obesity. Charlotte added: "Competition horses are likely to be managed in different ways compared to non-competition or non-ridden animals and this may also contribute to the reduced risk of obesity within this sub-population."
World Horse Welfare's Deputy Head of UK Support, Sam Chubbock said: "Excess weight is one of the greatest challenges facing horse owners in the UK today, which is why we supported this vital research. Being overweight can be just as much, if not more, of a health concern as being underweight. In our experience it can take three times longer to get an overweight horse back to optimum condition than it can a thin horse. Moreover, a previously obese horse's weight will need to be managed for the rest of its life, even after the weight has come off, and they are likely to suffer long-term effects. Managing a horse prone to weight gain can be incredibly difficult and this is why our Right Weight project provides practical guidance for owners on how to assess and manage their own horse's weight."
The AHT says its obesity research has helped to highlight obesity as a significant equine welfare issue and provided valuable information for owners. People frequently misclassify their own weight or body shape, and this phenomenon also applies to perceptions about our pets' weight. Dog and horse owners have been demonstrated to underestimate their animals' weight, suggesting the prevalence of obesity in this study is likely to be an underestimation.
Charlotte said: "It is possible that in certain breeds, being overweight or obese has been normalised to a certain extent. Owners may find it easier to identify an overweight Thoroughbred, compared to an overweight cob or native pony.
"Helping owners identify when their horse is overweight or obese is an essential aspect of reducing the welfare impact of equine obesity."
XLEquine and the Animal Health Trust (AHT) have launched Plan, Prevent, Protect, billed as the UK's first equine biosecurity booklet for horse owners and yard managers to work through with their veterinary surgeon, to minimise disease risk on yards and maintain the health and welfare of the horses in their care.
Mark Tabachnik MRCVS, of XLEquine member practice Wright & Morten Veterinary Surgeons said: "For many yard and horse owners, biosecurity is just not on their radar. It only becomes important after they have had an outbreak! Strangles in particular can have devastating effects which impact not only on horse welfare, but the disruption and paralysis of animal movement has significant consequences with relationships on the yard, not to mention the financial costs in some cases.
"We wanted to develop a practical guide that pre-empts these issues by helping owners to set in place simple and in many cases common sense, plans and procedures to prevent a disease outbreak, along with practical steps should the worst happen, and an outbreak occurs.
"Our veterinary farm colleagues and the medical profession are well ahead in terms of biosecurity measures. It's about changing people's mind-sets. For example the NHS "Catch it Bin it Kill it" campaign has been highly successful in adapting our thoughts and actions towards disease spread, and consequently many of us are more aware of the importance of good biosecurity in one way or another."
Dr Richard Newton, Head of Epidemiology and Disease Surveillance at the AHT was also involved in the development of the booklet. He said: "I hope that this will encourage all equine practices to raise their game, it is so important for the whole equine community."
The booklet is available to all equine clients of XLEquine member practices, or it is available to view at http://www.xlequine.co.uk/content/plan-prevent-protect
Merial has announced the launch of a new Blippar app designed to educate horse owners about gastric ulcers.
By using the app - which is available free from the App Store for iPhone or Google Play for Android phones - to scan the company's Gastrogard (omeprazole) adverts, posters or website, clients can watch an educational film with one of the UK's leading specialists in equine ulcers, Richard Hepburn BVSc MS(Hons) CertEM(IntMed) DipACVIM(LA) MRCVS, American and RCVS Specialist in Equine Internal Medicine, demonstrating the signs of ulcers and diagnosis via gastroscopy.
Merial's Equine Marketing and Technical Manager Louise Radford MRCVS said: "With 60% of competition horse and 38% of leisure horses & ponies estimated to have gastric ulcers¹,²,³, it's important that horse owners are aware of the signs of this under-diagnosed condition.
"We know that the number of horses diagnosed and treated for ulcers falls significantly short of incidence levels. We hope that this app will help to raise awareness and prompt more horse owners to consult their vet about gastric ulceration."
A separate Blippar app is also available for horse owners that have been prescribed GastroGard. By scanning the pack, clients can view educational video footage on gastric ulcers, find management tips on treatment and prevention, and set a reminder for future risk periods.
For more information, visit: http://www.equinegastriculcers.co.uk, contact your local Merial equine territory specialist or call Merial Customer Support on 0870 6000123.